Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive Disorder

Recently completed Phase 2 proof of concept study showed drug signal for troriluzole augmentation in OCD and pivotal Phase 3 trial now initiated Phase 3 trial enhancements include increased sample size to adequately power for previously observed treatme... Biopharmaceuticals Biohaven Pharmaceutical, troriluzole, Obsessive-Compulsive Disorder
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news